Genmab A/S (CPH:GMAB)

Denmark flag Denmark · Delayed Price · Currency is DKK
1,840.50
-12.00 (-0.65%)
Sep 26, 2025, 4:59 PM CET
-0.65%
Market Cap114.03B
Revenue (ttm)23.16B
Net Income (ttm)8.71B
Shares Out61.55M
EPS (ttm)137.33
PE Ratio13.49
Forward PE16.31
Dividendn/a
Ex-Dividend Daten/a
Volume109,462
Average Volume133,859
Open1,831.50
Previous Close1,852.50
Day's Range1,794.00 - 1,849.50
52-Week Range1,157.00 - 1,878.50
Beta0.80
RSI71.14
Earnings DateNov 6, 2025

About Genmab

Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large Bcell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell no... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1998
Employees 2,682
Stock Exchange Copenhagen Stock Exchange
Ticker Symbol GMAB
Full Company Profile

Financial Performance

In 2024, Genmab's revenue was $2.99 billion, an increase of 22.32% compared to the previous year's $2.44 billion. Earnings were $1.09 billion, an increase of 68.72%.

Financial numbers in USD Financial Statements

News

Grant of Restricted Stock Units and Warrants to Employees in Genmab

Company Announcement COPENHAGEN, Denmark; September 26, 2025 – Genmab A/S (Nasdaq: GMAB) announced today that the Board of Directors decided to grant 14,353 restricted stock units and 9,681 warrants t...

23 hours ago - GlobeNewsWire

Genmab A/S (GMAB) Presents at Bank of America Global Healthcare Conference 2025 Transcript

Genmab A/S (GMAB) Bank of America Global Healthcare Conference 2025 September 23, 2025 6:35 AM EDTCompany ParticipantsAnthony Pagano - Executive VP &...

1 day ago - Seeking Alpha

GMAB: Guggenheim Upgrades Genmab's Rating to 'Buy' on September 24, 2025 | GMAB Stock News

GMAB: Guggenheim Upgrades Genmab's Rating to 'Buy' on September 24, 2025 | GMAB Stock News

2 days ago - GuruFocus

Genmab (GMAB) Upgraded to Buy by Guggenheim Amid Growth Prospects

Genmab (GMAB) Upgraded to Buy by Guggenheim Amid Growth Prospects

3 days ago - GuruFocus

Genmab (GMAB) Ownership Update: Orbis Manages Over 5% Stake

Genmab (GMAB) Ownership Update: Orbis Manages Over 5% Stake

3 days ago - GuruFocus

Guggenheim Upgrades Genmab (GMAB) to Buy, Sets Price Target at $43 | GMAB Stock News

Guggenheim Upgrades Genmab (GMAB) to Buy, Sets Price Target at $43 | GMAB Stock News

3 days ago - GuruFocus

Major Shareholder Announcement

Company Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark; September 23, 2025 – Genmab A/S (Nasdaq: GMAB) announces under reference to Section 30 of the Danish Capital Mar...

3 days ago - GlobeNewsWire

Genmab Transitioning To A Global Oncology Powerhouse: Why I Choose To Buy

Genmab is expanding beyond royalties with strong drug sales, a deep oncology pipeline, and $2.9B in cash, supporting long-term growth. Learn why GMAB stock is a buy.

12 days ago - Seeking Alpha

Genmab: Epkinly's Spectacular Data Is The Antidote To The Darzalex Patent Cliff

Genmab A/S is leveraging its royalty-centric model and new ADCs like Epkinly to offset upcoming Darzalex patent expiry risks. Epkinly's strong Phase 3 data in follicular lymphoma positions GMAB for bl...

14 days ago - Seeking Alpha

Genmab: A Matter Of Time

14 days ago - Seeking Alpha

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Company Announcement COPENHAGEN, Denmark; September 9, 2025 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523,...

17 days ago - GlobeNewsWire

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Company Announcement COPENHAGEN, Denmark; September 09, 2025 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 47,532 shares as a consequence of the exercise of employee warrants. The inc...

17 days ago - GlobeNewsWire

10 stocks to consider if you want alternatives to the expensive S&P 500

Stocks in developed economies outside the U.S. tend to trade at lower valuations. Some of the companies are expected to expand their businesses rapidly over the next two years.

17 days ago - Market Watch

AbbVie updates mid-stage trial data for Genmab-partnered lymphoma drug in outpatient setting

AbbVie (ABBV) stock in focus as the company posts new data from a mid-stage trial for its lymphoma drug epcoritamab developed with Genmab. Read more here.

23 days ago - Seeking Alpha

Genmab Announces Updated Results from Phase 2 EPCORE® NHL-6 Study Evaluating Epcoritamab Monotherapy in the Outpatient Setting in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Media Release COPENHAGEN, Denmark; September 3, 2025 Trial demonstrated the feasibility of treating and monitoring adult patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) i...

23 days ago - GlobeNewsWire

Genmab Announces Updated Results from Phase 2 EPCORE® NHL-6 Study Evaluating Epcoritamab Monotherapy in the Outpatient Setting in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced updated results from the Phase 2 EPCORE® NHL-6 trial (NCT05451810) evaluating the safety and efficacy of investigational...

23 days ago - Business Wire

Genmab to Participate in a Fireside Chat at the Morgan Stanley 23rd Annual Global Healthcare Conference

Media Release COPENHAGEN, Denmark; August 26, 2025 Genmab A/S (Nasdaq: GMAB) announced today that its Chief Executive Officer Jan Van de Winkel and C hief F inancial O fficer Anthony Pagano will part...

4 weeks ago - GlobeNewsWire

Genmab Receives FDA Breakthrough Therapy Designation for Rinatabart Sesutecan (Rina-S®) in Advanced Endometrial Cancer (EC)

Media Release COPENHAGEN, Denmark; August 26, 2025 Breakthrough Therapy Designation granted to Rina-S for the treatment of adult patients with recurrent or progressive endometrial cancer (EC) who have...

4 weeks ago - GlobeNewsWire

Genmab Receives FDA Breakthrough Therapy Designation for Rinatabart Sesutecan (Rina-S®) in Advanced Endometrial Cancer (EC)

COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to rinatabart sesute...

4 weeks ago - Business Wire

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Company Announcement COPENHAGEN, Denmark; August 12, 2025 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 4,563 shares as a consequence of the exercise of employee warrants. The increas...

6 weeks ago - GlobeNewsWire

Genmab/AbbVie Partnered Blood Cancer Combination Drug Cuts Risk Of Disease Progression By 79%

Genmab A/S (NASDAQ: GMAB) released results Thursday of the Phase 3 EPCORE FL-1 trial evaluating subcutaneous epcoritamab in combination with rituximab and lenalidomide (R2) versus R2 alone for adult ...

7 weeks ago - Benzinga

Genmab/AbbVie Partnered Blood Cancer Combination Drug Cuts Risk Of Disease Progression By 79%

Genmab A/S GMAB released results Thursday of the Phase 3 EPCORE FL-1 trial evaluating subcutaneous epcoritamab in combination with rituximab and lenalidomide (R2) versus R2 alone for adult patients wi...

7 weeks ago - Benzinga